Effect of Aspirin on Incidence of Pre-Eclampsia

Crandon, Alex J.; Isherwood, D. M.

doi:10.1016/s0140-6736(79)91996-2

Cited by 100 publications

(43 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1979, Crandon and Isherwood found that women taking aspirin for other reasons were less likely to develop pre‐eclampsia, and Masotti et al . demonstrated a different inhibition of cyclo‐oxygenase in platelets and vessel walls by low doses of aspirin. Six years later, Beaufils et al .…”

Section: Discussionmentioning

confidence: 99%

Prevention of perinatal death and adverse perinatal outcome using low‐dose aspirin: a meta‐analysis

Roberge

Nicolaides

Demers

et al. 2013

Ultrasound in Obstet & Gyne

348

237

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Prevention of perinatal death and adverse perinatal outcome using low‐dose aspirin: a meta‐analysis

Roberge

Nicolaides

Demers

et al. 2013

Ultrasound in Obstet & Gyne

348

237

View full text Add to dashboard Cite

show abstract

“…Since 1979, when the utility of aspirin intake in pregnancy was reported to prevent PE (17), many reports with controversial results on the efficiency of this drug were reported: two multicenter studies found a slight benefit of aspirin in preventing PE (35, 36). Other randomized placebo-controlled trials suggest that LDA did not reduce the rate of PE [relative risk (RR), 0.7, 95% confidence interval (CI), 0.3–1.7] (37).…”

Section: Use Of Aspirin In Prevention Of Pementioning

confidence: 99%

Aspirin: The Mechanism of Action Revisited in the Context of Pregnancy Complications

Cadavid

2017

Front. Immunol.

100

View full text Add to dashboard Cite

Aspirin is one of the most frequently used and cheapest drugs in medicine. It belongs to the non-steroidal anti-inflammatory drugs with a wide range of pharmacological activities, including analgesic, antipyretic, and antiplatelet properties. Currently, it is accepted to prescribe a low dose of aspirin to pregnant women who are at high risk of preeclampsia (PE) because it reduces the onset of this complication. Another pregnancy alteration in which a low dose of aspirin is recommended is the obstetric antiphospholipid syndrome (APS). The most recognized mechanism of action of aspirin is to inhibit the synthesis of prostaglandins but this by itself does not explain the repertoire of anti-inflammatory effects of aspirin. Later, another mechanism was described: the induction of the production of aspirin-triggered lipoxins (ATLs) from arachidonic acid by acetylation of the enzyme cyclooxygenase-2. The availability of a stable analog of ATL has stimulated investigations on the use of this analog and it has been found that, similar to endogenously produced lipoxins, ATL resolves inflammation and acts as antioxidant and immunomodulator. If we consider that in PE and in the obstetric APS, there is an underlying inflammatory process, aspirin might be used based on the induction of ATL. The objective of this review is to revisit the old and new mechanisms of action of aspirin. In particular, it intends to show other potential uses of this drug to prevent certain pregnancy complications in the light of its ability to induce anti-inflammatory and pro-resolving lipid-derived mediators.

show abstract

“…The hypothesis that aspirin could prevent preeclampsia was developed in 1979, when it was observed that women who were taking aspirin for other reasons were less likely to develop preeclampsia than women who were not 1. In 1985, it was found that 150 mg of aspirin taken daily and started at 12 weeks’ gestation reduced the rate of preeclampsia, IUGR and perinatal death 2 3.…”

Section: Commentarymentioning

confidence: 99%

Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia

Bujold

2015

Evid Based Nurs

View full text Add to dashboard Cite

Commentary on: Henderson JT, Whitlock EP, O'Connor E, et al. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive services task force. Ann Intern Med 2014;160:695-703. Implications for practice and research▪ Daily low-dose aspirin is recommended from 12 weeks' gestation and onward to women identified at high-risk for preeclampsia.▪ While women with chronic hypertension or personal history of preeclampsia should receive aspirin during pregnancy, further research leading to first-trimester prediction of preeclampsia in low-risk women should be encouraged. ContextPreeclampsia affects 2-8% of pregnancies and is a leading cause of maternal deaths around the world. It is associated with poor perinatal outcome, primarily due to increased risk of intrauterine growth restriction (IUGR) and medically indicated preterm delivery. Over the last three to four decades, there has been a debate regarding the use of low-dose aspirin for the prevention of preeclampsia and its consequences. Henderson and colleagues reviewed the literature that evaluated the impact of low-dose aspirin during pregnancy. MethodsThe purpose of the study was to collect and analyse the best evidence regarding the effect of low-dose aspirin during pregnancy. The authors performed a systematic review of English-language literature, including randomised controlled trials (RCTs), that assessed the benefits of low-dose aspirin during pregnancy as well as RCTs and large cohort studies that assessed its potential harms. Meta-analyses were performed to estimate the effect on preeclampsia, IUGR and preterm birth. FindingsThe review included 21 studies. The authors concluded that low-dose aspirin could reduce the absolute risk of preeclampsia, IUGR and preterm birth by about 1-5% (with relative risk reductions ranging from 14-24%). No significant perinatal or maternal harms were identified, but rare harms could not be ruled out. Available data were insufficient to determine the optimal gestational age when aspirin should be initiated and the optimal dosage that should be recommended. The US Preventive Services Task Force recommends that women identified at high-risk for preeclampsia should take 81 mg of aspirin daily beginning after the 12th week of pregnancy. CommentaryThe hypothesis that aspirin could prevent preeclampsia was developed in 1979, when it was observed that women who were taking aspirin for other reasons were less likely to develop preeclampsia than women who were not. 1 In 1985, it was found that 150 mg of aspirin taken daily and started at 12 weeks' gestation reduced the rate of preeclampsia, IUGR and perinatal death. 2 3 Thereafter more than 60 RCTs were published with contradicting results. However, those trials were heterogeneous in terms of: aspirin dosage (from less than 50 to150 mg daily); gestational age at recruitment (from 7-32 weeks' of gestation); and risk of preeclampsia. Meta-analyses can help to determine the effect of a treatment but the conclusions are lim...

show abstract

Effect of Aspirin on Incidence of Pre-Eclampsia

Cited by 100 publications

References 9 publications

Prevention of perinatal death and adverse perinatal outcome using low‐dose aspirin: a meta‐analysis

Prevention of perinatal death and adverse perinatal outcome using low‐dose aspirin: a meta‐analysis

Aspirin: The Mechanism of Action Revisited in the Context of Pregnancy Complications

Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia

Contact Info

Product

Resources

About